Silence of p15 expression by RNAi enhances cisplatin resistance in hepatocellular carcinoma cells

Bosnian Journal of Basic Medical Sciences

Volumn 12, Issue 1, 2012, Pages 4-9

  Fang, Dianliang ^a   Guo, Yuanhong ^a   Zhu, Zhenshuang ^a   Chen, Weiqing ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Drug resistance; Hepatocellular carcinoma; P15; RNA interference

Indexed keywords

EID: 84863289408     PISSN: 15128601     EISSN: 18404812     Source Type: Journal    
DOI: 10.17305/bjbms.2012.2523     Document Type: Article

References (23)

1. Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13(9): S169-171.
2. Shi LX, Ma R, Lu R, Xu Q, Zhu ZF, Wang L, et al. Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-74o2/s-FU. Cancer Lett. 2008; 269(1):101-110.
3. Jacqueline Whang-Peng, Ann-Lii Cheng, Chiun Hsu, Chien-Ming Chen. Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. J Exp Clin Med. 2010; 2(3):93-103.
4. Fojo T. Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat. 2007;10(1-2):59-67.
5. Shah MA, Schwartz GK. Cyclin dependent kinases as targets for cancer therapy. Update on cancer therapeutics 2006, 1(3):311-332.
6. Shah MA, Schwartz GK. Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy. Clin Cancer Res. 2001, 7:2168-2181.
7. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003; 36:131-149.
8. Jeffrey PD, Tong L, Pavletich NP. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. Genes Dev. 2000; 14(24):3115-3125.
9. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature. 2004;430(6996):226-31.
10. Sakellariou S, Liakakos T, Ghiconti I, Hadjikokolis S, Nako-poulou L, Pavlakis K. Immunohistochemical expression of Pis (INK4B) and SMAD4 in advanced gastric cancer. Anticancer Res. 2008;28(2A):1079-1083.
11. Rosu-Myles M, Wolff L. pisInk4b: Dual function in myelopoi-esis and inactivation in myeloid disease. Blood Cells Mol Dis. 2008;40(3):406-409.
12. Musat M, Morris DG, Korbonits M, Grossman AB. Cyclins and their related proteins in pituitary tumourigenesis. Mol Cell Endo-crinol. 2010; 326(1-2):25-29.
13. MK4c cell cycle inhibitors in proliferation and tumorigenesis. EMBO J. 2000;19(13):3496-3506.
14. Wang W, Chen WQ. MDR-reversing effect of Pis to multi-drug-resistant hepatocellular carcinoma cells. J Fourth Mil Med Univ. 2009; 30(15):1383-1386.
15. Gan SY, Zhong XY, Xie SM, Li SM, Peng H, Luo F. Expression and significance of tumor drug resistance related proteins and beta-catenin in esophageal squamous cell carcinoma. Chin J Cancer. 2010; 29(3):323-329.
16. Warmann S, Hunger M, Teichmann B, Flemming P, Gratz KF, Fuchs J. The Role of the MDRi Gene in the Development of Multi-drug Resistance in Human Hepatoblastoma: clinical course and in vivo model. Cancer. 2002;95(8):1795-1801.
17. Manish A.Shah, Gary K. Schwartz. Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy. Clin Cancer Res. 2001;7: 2168-2181.
18. Endicott JA, Ling V. The Biochemistry of P-Glycoprotein-Mediat-ed Multidrug Resistance. Annu Rev Biochem. 1989; 58:137-171.
19. Boulikas T. Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin. Lipoplatin as a chemotherapy and antiangiogenesis drug. Cancer Therapy. 2007,5:351-376.
20. Yang JX, Tang WX. Establishment of a cisplatin-induced human hepatocellular carcinoma drug-resistant cell line and its biological characteristics. Ai Zheng. 2002; 21(8):872-876.
21. Liu TG, Yin JQ, Shang BY, Min Z, He HW, Jiang JM, et al. Silencing of hdm2 oncogene by siRNA inhibits ps3-dependent human breast cancer. Cancer Gene Ther. 2004;11(11):748-756.
22. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. 2005;12(3):217-227.
23. Novina CD, Sharp PA. The RNAi revolution. Nature. 2004;430:161-164.